RSS   Newsletter   Contact   Advertise with us

Dyadic appoints chairman of the board of directors

Staff writer | Jupiter, Fla., USA | January 13, 2015
DyadicJanuary 13, 2015, Jupiter, Fla., USA - Dyadic International, Inc., a biotechnology company, announced the appointment of Michael Tarnok as the company's chairman of the board of directors.
Mr. Tarnok will continue to serve on the company's audit and compensation committees. Mr. Tarnok has extensive experience in the pharmaceutical industry across many key areas including finance, operations and marketing. He is also the current Chairman and former Interim CEO of Keryx Biopharmaceuticals, Inc., a biotechnology company focused on the development of therapeutics for renal disease.

Prior to joining Keryx as a Director in 2007, Mr. Tarnok spent the majority of his career at Pfizer Inc., joining in 1989 as Director of Finance for U.S. Manufacturing. From 2000-2007, he served as Senior Vice President in Pfizer's U.S. Pharmaceuticals Division.

Prior to joining Pfizer, he worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation, and Olivetti Corporation of America.

Mr. Tarnok earned an MBA in marketing from New York University and a Bachelor of Science in accounting from St. John's University. He also serves on the Board of the Global Health Counsel, a Washington, D.C.-based NGO.